Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Jones

Showing results (181-190 of 210) with videos related to

Pageof 21
Sort By:
Pulmonary Therapy|March 6, 2024
Association between Increased Risk of Pneumonia with ICS in COPD: A Continuous Variable Analysis of Patient Factors from the IMPACT StudyBhumika Aggarwal, Paul Jones, Alejandro Casas, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2002
Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A proteaseMartin J Slater, David M Andrews, Graham Baker, et al.
Journal of Toxicology and Environmental Health. Part B, Critical Reviews|December 21, 2010
An exposure-response curve for copper excess and deficiencyAndrea Chambers, Daniel Krewski, Nicholas Birkett, et al.
Bioorganic & Medicinal Chemistry Letters|October 6, 2009
N,N-Diethyl-4-[(3-hydroxyphenyl)(piperidin-4-yl)amino] benzamide derivatives: the development of diaryl amino piperidines as potent delta opioid receptor agonists with in vivo anti-nociceptive activity in rodent modelsPaul Jones, Andrew M Griffin, Lars Gawell, et al.
Theranostics|May 23, 2017
[<sup>18</sup>F]GE-180 PET Detects Reduced Microglia Activation After LM11A-31 Therapy in a Mouse Model of Alzheimer's DiseaseMichelle L James, Nadia P Belichenko, Adam J Shuhendler, et al.
ERJ Open Research|September 16, 2021
Investigation of the Clinical, Radiological and Biological Factors Associated with Disease Progression, Phenotypes and Endotypes of COPD in China (COMPASS): study design, protocol and rationaleZhenyu Liang, Nanshan Zhong, Rongchang Chen, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|December 31, 2021
Higher COPD Assessment Test Score Associated With Greater Exacerbations Risk: A Post Hoc Analysis of the IMPACT TrialByron Thomashow, Marjorie Stiegler, Gerard J Criner, et al.
JAMA Network Open|September 29, 2021
Symptoms and Health Outcomes Among Survivors of COVID-19 Infection 1 Year After Discharge From Hospitals in Wuhan, ChinaXue Zhang, Fang Wang, Ye Shen, et al.
British Journal of Cancer|February 14, 2018
A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424Victoria K Woodcock, Sally Clive, Richard H Wilson, et al.
Brain Communications|September 8, 2023
The comparable tumour microenvironment in sporadic and <i>NF2</i>-related schwannomatosis vestibular schwannomaGrace E Gregory, Adam Paul Jones, Michael J Haley, et al.
Pageof 21

Showing results (181-190 of 210) with videos related to

Sort By:
Pageof 21
Pulmonary Therapy|March 6, 2024
Association between Increased Risk of Pneumonia with ICS in COPD: A Continuous Variable Analysis of Patient Factors from the IMPACT StudyBhumika Aggarwal, Paul Jones, Alejandro Casas, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2002
Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A proteaseMartin J Slater, David M Andrews, Graham Baker, et al.
Journal of Toxicology and Environmental Health. Part B, Critical Reviews|December 21, 2010
An exposure-response curve for copper excess and deficiencyAndrea Chambers, Daniel Krewski, Nicholas Birkett, et al.
Bioorganic & Medicinal Chemistry Letters|October 6, 2009
N,N-Diethyl-4-[(3-hydroxyphenyl)(piperidin-4-yl)amino] benzamide derivatives: the development of diaryl amino piperidines as potent delta opioid receptor agonists with in vivo anti-nociceptive activity in rodent modelsPaul Jones, Andrew M Griffin, Lars Gawell, et al.
Theranostics|May 23, 2017
[<sup>18</sup>F]GE-180 PET Detects Reduced Microglia Activation After LM11A-31 Therapy in a Mouse Model of Alzheimer's DiseaseMichelle L James, Nadia P Belichenko, Adam J Shuhendler, et al.
ERJ Open Research|September 16, 2021
Investigation of the Clinical, Radiological and Biological Factors Associated with Disease Progression, Phenotypes and Endotypes of COPD in China (COMPASS): study design, protocol and rationaleZhenyu Liang, Nanshan Zhong, Rongchang Chen, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|December 31, 2021
Higher COPD Assessment Test Score Associated With Greater Exacerbations Risk: A Post Hoc Analysis of the IMPACT TrialByron Thomashow, Marjorie Stiegler, Gerard J Criner, et al.
JAMA Network Open|September 29, 2021
Symptoms and Health Outcomes Among Survivors of COVID-19 Infection 1 Year After Discharge From Hospitals in Wuhan, ChinaXue Zhang, Fang Wang, Ye Shen, et al.
British Journal of Cancer|February 14, 2018
A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424Victoria K Woodcock, Sally Clive, Richard H Wilson, et al.
Brain Communications|September 8, 2023
The comparable tumour microenvironment in sporadic and <i>NF2</i>-related schwannomatosis vestibular schwannomaGrace E Gregory, Adam Paul Jones, Michael J Haley, et al.
Pageof 21